An eruption of investment and company creation in Chinese biotech has signaled the dawn of a raw but promising market. First-movers must negotiate immediate pitfalls while targeting long-term upside
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.
LeapFrog Investments has acquired a majority stake in India-base healthcare industry supplier Ascent Meditech for an undisclosed sum.
Lakeshore Capital has taken a controlling stake in domestic drug manufacturer Devakam Apothecary Hall, owner of the Namman Muay analgesic cream brand, for an undisclosed amount.
Indian healthcare service provider Fortis Healthcare (FHL) has chosen IHH Healthcare as the buyer for its hospital operation, ending a protracted bidding process and rejecting a INR32 billion ($472 million) offer from TPG Capital and its portfolio company...
Flipkart sets the tone as strategics deliver tech trade sale exits; Chinese internet players and healthcare are the trendsetters in investment; buyouts, venture stand out in Asia fundraising
Long Hill Capital, a Chinese venture capital firm that spun out from New Enterprise Associates (NEA) in 2016, has raised $252.2 million for its second VC fund.
Asia Healthcare Holdings (AHH), a healthcare-focused operating and investment platform managed by TPG Growth, has raised $50 million from Singapore’s Temasek Holdings.
China’s Yungfeng Capital has teamed up with Shenzhen-based Hybio Pharmaceutical to acquire diversified German biopharmaceuticals company AMW for an undisclosed sum.
C-Bridge Capital has reached a first close of just over $400 million on its third healthcare fund, which focuses on Chinese pharmaceutical, medical technology and healthcare services companies with proven products and technologies.
Vivo Capital and Advantech Capital have committed $86.73 million to Chinese biopharmaceutical player Sinovac Biotech. Both investors were members of a consortium that was bidding to privatize the US-listed company, but that process has been terminated.
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
YuanMing Capital and Matrix Partners China have led a Series B round of more than $50 million – denominated in US dollars and renminbi – for Adlai Nortye, a Chinese biopharmaceutical company.
General Atlantic has committed $130 million to Krishna Institute of Medical Sciences (KIMS), a South India-based hospital chain that has been approved for an IPO. The company is also backed by ICICI Venture.
C-Bridge Capital, a Chinese healthcare-focused private equity firm, has led a $20 million Series B funding round for domestic pharmaceuticals developer Nuance Biotech.
Accel Partners and IDG Ventures have led a $19 million Series B round for Indian healthcare-focused artificial intelligence (AI) start-up SigTuple.
OneVentures co-founder Michelle Deaker leveraged a background of IT innovation to introduce a much-needed dose of entrepreneurialism into the early days of Australia’s venture capital industry
China Renaissance Holdings has filed for an IPO in Hong Kong that will support the expansion of its investment banking, investment management, and wealth management businesses. AVCJ understands the firm is planning to raise $800 million at a valuation...
The move to allow zero-revenue biotech companies to list in Hong Kong has spurred investor interest in healthcare. But valuations are high and success in this capital-intensive space is by no means guaranteed
China’s Qiming Venture Partners has led a $37 million Series A investment in domestic biopharmaceutical start-up Alpha Biopharma.
CITIC Capital has submitted a take-private bid for China Biologic Products that values the US-listed biopharmaceutical developer at approximately $3.65 billion.
SeaLink Capital Partners has led a INR2 billion ($29 million) investment in Indian maternal and pediatric hospital chain Surya Children’s Medicare, providing an exit for OrbiMed Advisors.
Chinese B2B pharmaceutical trading and education platform Yaoshibang has received RMB420 million ($65 million) in Series C funding across two tranches.
Australian medical device manufacturer Sirtex Medical has accepted a A$1.9 billion ($1.4 billion) buyout offer from China’s CDH Investments, pulling the plug on an earlier agreement with US-listed Varian Medical Systems.